Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;18(5):1094-1099.
doi: 10.1111/jth.14817. Epub 2020 Apr 27.

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Ning Tang  1 , Huan Bai  1 , Xing Chen  1 , Jiale Gong  1 , Dengju Li  2 , Ziyong Sun  1
Affiliations

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Ning Tang et al. J Thromb Haemost. 2020 May.

Abstract

Background: A relatively high mortality of severe coronavirus disease 2019 (COVID-19) is worrying, and the application of heparin in COVID-19 has been recommended by some expert consensus because of the risk of disseminated intravascular coagulation and venous thromboembolism. However, its efficacy remains to be validated.

Methods: Coagulation results, medications, and outcomes of consecutive patients being classified as having severe COVID-19 in Tongji hospital were retrospectively analyzed. The 28-day mortality between heparin users and nonusers were compared, as was a different risk of coagulopathy, which was stratified by the sepsis-induced coagulopathy (SIC) score or D-dimer result.

Results: There were 449 patients with severe COVID-19 enrolled into the study, 99 of them received heparin (mainly with low molecular weight heparin) for 7 days or longer. D-dimer, prothrombin time, and age were positively, and platelet count was negatively, correlated with 28-day mortality in multivariate analysis. No difference in 28-day mortality was found between heparin users and nonusers (30.3% vs 29.7%, P = .910). But the 28-day mortality of heparin users was lower than nonusers in patients with SIC score ≥4 (40.0% vs 64.2%, P = .029), or D-dimer >6-fold of upper limit of normal (32.8% vs 52.4%, P = .017).

Conclusions: Anticoagulant therapy mainly with low molecular weight heparin appears to be associated with better prognosis in severe COVID-19 patients meeting SIC criteria or with markedly elevated D-dimer.

Keywords: D-dimer; coagulopathy; coronavirus disease 2019; low molecular weight heparin; sepsis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The enrollment of patients with severe COVID‐19
Figure 2
Figure 2
A paired bar chart showing the mortality between heparin users and nonusers in stratified patients. D‐D, D‐dimer; SIC+, SIC score ≥ 4; SIC−, SIC score < 4; ULN, upper limit of normal (0.5 μg/mL); a, P < .05 between heparin users and nonusers
See this image and copyright information in PMC

Comment in

References

    1. Chen N., Zhou M., Dong X., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. - PMC - PubMed
    1. Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. - PMC - PubMed
    1. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020 doi: 10.1111/jth.14768. - DOI - PMC - PubMed
    1. Singer M., Deutschman C.S., Seymour C.W., et al. The third international consensus definitions for sepsis and septic shock (Sepsis‐3) JAMA. 2016;315(8):801–810. - PMC - PubMed
    1. Shanghai Clinical Treatment Expert Group for. COVID‐19 Comprehensive treatment and management of coronavirus disease 2019: expert consensus statement from Shanghai (in Chinese) Chin J Infect Dis. 2020;38 doi: 10.3760/cma.j.issn.1000-6680.2020.0016. - DOI

Publication types

MeSH terms